Gene Solutions won US FDA Breakthrough Device Designation for SPOT-MAS 10, a multiomic early detection blood test aimed at asymptomatic adults. The assay combines machine-learning analysis of circulating cell-free DNA methylation and fragmentomic signatures to screen for 10 cancer types. The test is designed as an adjunctive lab-developed test for people aged 40 and older, targeting both common malignancies (including breast, lung, colorectal, gastric, and liver) and several aggressive but less frequent cancers. Gene Solutions said the designation validates the company’s multiomics approach for shifting screening toward earlier intervention. Gene Solutions previously partnered with Pangea Laboratories for US-based analytical and clinical validation, with Pangea potentially running testing at its Irvine, California lab. The designation may accelerate interactions with regulators for evidence planning and clinical study design as the program moves toward potential broader adoption.